Clinical Trial

Naltrexone Neuroimaging in Teens With Eating Disorders

Study acronym: NN-RCT
Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
Using a randomized, placebo-controlled, crossover study, this study will evaluate functional magnetic resonance imaging (fMRI) as a pharmacodynamic biomarker of opioid antagonism in adolescents with eating disorders. The hypothesis is that fMRI will be able to detect acute reward pathway modulation by naltrexone (an opioid antagonist) in pre-defined regions of interest (anterior cingulate cortex, nucleus accumbens, dorsolateral prefrontal cortex).
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2022-08-18; most recent amendment 2025-11-20.
Status change: Not Yet Recruiting → Recruiting 2022-10-17
Trial Details
NCT Number NCT05509257
Lead Sponsor Children's Mercy Hospital Kansas City
Collaborators: University of Kansas Medical Center, National Institute of Mental Health (NIMH)
Conditions Eating Disorders, Binge Eating, Purging (Eating Disorders), Bulimia Nervosa, Anorexia Nervosa, Atypical
Enrollment 60 participants
Start Date 2022-09-17
Primary Completion 2026-09 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2025-11-25